REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2014

Nov 12, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2014-11-12

Reporting Person: GOLDSTEIN JOSEPH L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-11-12	Common Stock	M	5000.0	$177.82	Acquired	9000	Direct
2014-11-12	Common Stock	S	5000.0	$398.31	Disposed	4000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-11-12	Non-Qualified Stock Option (right to buy)	$177.82	M	5000.0	Disposed	2023-01-02	Common Stock (5000)	Direct

Footnotes

F1: Represents volume-weighted average price of sales of 5,000 shares of Company stock on November 12, 2014 at prices ranging from $398.15 to $399.12. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 12, 2014 at each separate price.

F2: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.